The global preimplantation genetic testing market is growing steadily, valued at around US$ 598.4 million in 2026 and ...

Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national ...

"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...

The global preimplantation genetic testing market is growing steadily, valued at around US$ 598.4 million in 2026 and projected to reach US$ 1,081.9 million ...